Claim: Nifurtimox is indicated in children and adolescents for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi, and also for the treatment of African trypanosomiasis (an insect-borne parasitic infection causing sleeping sickness).
Evidence: In the United States nifurtimox is indicated in children and adolescents (birth to less than 18 years of age and weighing at least 2.5 kilograms (5.5 lb) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi. Nifurtimox has also been used to treat African trypanosomiasis (sleeping sickness), and is active in the second stage of the disease (central nervous system involvement).